TREA

79392996 - BDC

Follow

Information

  • Trademark
  • 79392996
  • Serial Number
    79392996
  • Filing Date
    December 19, 2023
    a year ago
  • Transaction Date
    January 24, 2025
    13 days ago
  • Status Date
    January 23, 2025
    14 days ago
  • Published for Opposition Date
    February 11, 2025
    4 days from now
  • Location Date
    January 23, 2025
    14 days ago
  • Status Code
    681
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    ANDREACCHI,SAMANTHA ALEXIS
  • Attorney Docket Number
    601696
    Attorney Name
    Andrew D. Price & Paula E. Hopkins
    Law Office Assigned Location Code
    O30
  • Owners
Information
Mark Drawing Code
4
Mark Identification
BDC
Case File Statements
  • GS0051: Pharmaceutical preparations for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical preparations for use in preventing and treating infections; pharmaceutical products and preparations for the treatment of respiratory disease; pharmaceutical preparations for the treatment and prevention of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical preparations for use in medical diagnostics and imaging; pharmaceutical preparations for the treatment and prevention of renal disease; pharmaceutical preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical preparations for the treatment and prevention of muscular skeletal disease
  • GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research and new product design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; medical research services, namely, industrial analysis and research services in the field of medicine; research and development services in the field of pharmaceutical preparations; medical research services; pharmaceutical research services, namely, pharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consulting, namely, providing information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents
Case File Event Statements
  • 4/4/2024 - 10 months ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 7/1/2024 - 7 months ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/30/2024 - 6 months ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 8/17/2024 - 5 months ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 4/12/2024 - 10 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/18/2024 - 9 months ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 7/2/2024 - 7 months ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/3/2024 - 7 months ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 7/30/2024 - 6 months ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 12/16/2024 - a month ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/16/2024 - a month ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/21/2025 - 16 days ago
    16 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 1/21/2025 - 16 days ago
    15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 12/16/2024 - a month ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/21/2025 - 16 days ago
    14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/23/2025 - 14 days ago
    17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/21/2025 - 16 days ago
    13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA